Navigation Links
Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations
Date:12/15/2009

at no other breast cancer test has demonstrated the reproducible clinical utility that Genomic Health has established with Oncotype DX, the company's plan to continue to add value to its breast cancer test through ongoing research and clinical experience, the belief that using Oncotype DX can predict chemotherapy benefit in women with ER+, N+ disease, the belief that Oncotype DX frequently changes treatment recommendations with an overall reduction in chemotherapy, the belief that Oncotype DX may have a potential role in neoadjuvant treatment planning and the company's plans regarding additional studies in this regard, the belief that certain study results provide a rationale for evaluating currently available and investigational agents that target certain pathways, the company's plans to commercialize a test for colon cancer and the proposed timing of such commercialization, and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc.
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
2. New Genomic Test for Coronary Artery Disease Now Available at The Heart & Vascular Center of Arizona
3. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
4. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
5. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
6. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
7. Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development
8. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
9. Curemark CEO Presents at Epigenomics Conference
10. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
11. Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)...  Dohmen Company CEO Cynthia LaConte is ... of Commerce,s annual ,Future 50, Awards luncheon, to be ... ,Future 50, Awards highlights the achievements of 50 local, ... in the seven-county Milwaukee region. ... home for more than 150 years, and ...
(Date:9/4/2015)...  Luminex Corporation (NASDAQ: LMNX ) today announced ... Healthcare Conference to be held September 16 - 18, ... New York City . The investor ... Friday, September 18, 2015.  The presentation will be webcast live ... http://www.luminexcorp.com . Simply log on to the web at ...
(Date:9/4/2015)... , September 4, 2015 According ... Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure ... by Product - Global Forecast to 2020", published by ... USD 2.5 Billion by 2020, growing at a CAGR ... 2020. Browse 139 Tables and 45 ...
Breaking Medicine Technology:Dohmen CEO Cynthia LaConte to Keynote MMAC 'Future 50' Awards Luncheon 2Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5
... 2 Aerovance Inc. today announced that it ... Drug Administration (FDA) and the U.K. Medicines and ... Phase IIb clinical trial, AeroTrial(TM), of inhaled dry ... begins today in the United States for AeroTrial, ...
... Calif., March 2 Hana,Biosciences (Nasdaq: ... Monitoring,Committee (IDMC) has completed a planned, pre-specified safety ... clinical trial of Marqibo(R) (vincristine,sulfate liposomes injection) for ... second relapse. The results of the IDMC ...
Cached Medicine Technology:Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma 2Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma 3Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 2Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 3Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 4Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 5
(Date:9/5/2015)... FL (PRWEB) , ... September 05, 2015 , ... ... nutrition and supplementation and a top resource for all things fitness and motivation, ... extremely close race with over 20 brands competing for a variety of awards. ...
(Date:9/5/2015)... ... 2015 , ... "I have personally had three knee-replacement surgeries on the same ... "I came up with this idea so that I could not only support my ... the KNEE BUDDY to comfortably and safely support the knee while recovering from surgery ...
(Date:9/5/2015)... ... September 05, 2015 , ... Doctors in Chicago have ... is good for older patients. Surviving Mesothelioma has just posted an article on the ... Surgeons at the University of Chicago performed a retrospective analysis of 117 mesothelioma patients ...
(Date:9/5/2015)... ... September 05, 2015 , ... If you are nervous about either giving or ... is a greater need than ever before for an idea conceived of by an ... protect medical staff members and patients against accidental needle punctures. As such, it prevents ...
(Date:9/5/2015)... ... 05, 2015 , ... Watching a cyber nightmare come to life in the privacy of one’s ... nothing more than sit back helplessly as a hacker took control over their digital world, ... it may have made the whole situation that much more jarring to the senses for ...
Breaking Medicine News(10 mins):Health News:BPI Sports Wins Two Bodybuilding.com Supplement Awards 2Health News:BPI Sports Wins Two Bodybuilding.com Supplement Awards 3Health News:InventHelp Inventor Develops Therapeutic Knee Support (PHO-2061) 2Health News:New Study Appears to Validate the Safety of Mesothelioma Surgery for Older Patients, According to Surviving Mesothelioma 2Health News:Safety Feature for Needle Injections Invented by InventHelp Client (OCM-914) 2Health News:IT Security Beware: A Cyber Security Nightmare at Work Can Start at Home 2Health News:IT Security Beware: A Cyber Security Nightmare at Work Can Start at Home 3Health News:IT Security Beware: A Cyber Security Nightmare at Work Can Start at Home 4
... Seminar Provides Information Into Under Utilized Treatment Program, ... to women diagnosed with breast cancer without insurance ... -- and many healthcare,providers -- are not aware ... to benefit,breast cancer patients. That is why the ...
... Dec. 14 Mike Sacco and Lejon,Boudreaux are running ... days,withstanding bone-shattering pain, reckless drivers and tons of highway,debris ... the Multimedia News Release, go to:, http://www.prnewswire.com/mnr/blackaidsinstitute/31094/ , ... by June 27, 2009,which is National HIV Testing Day," ...
... helps women with HER2+ type of breast cancer independent ... home to the HER2 gene which produces the HER2 ... there were conflicting opinions about whether that was the ... at the San Antonio Breast Cancer Symposium. , ...
... Hosts First Annual Exclusive Wine ... Gala, WASHINGTON, Dec. 14 Starlight Starbright,Children,s ... Annual Exclusive Wine Dinner and Eighth Annual Taste ... events were hosted at the,award-winning Michel Richard Citronelle ...
... recent reports of the,Fig LipoDissolve Centers going into ... Surgeons (ASPS) and the American Society for,Aesthetic Plastic ... in treatment there or suffering from unwanted outcomes. ... for fat reduction,until appropriate research has documented the ...
... Online Help for Living Longer, ... Stronger, KIRKLAND, ... odds of needing long term care,increase. One solution is long term care insurance ... Financial Partners,(LTCFP), "is the insurance plus health habits to keep yourself on your ...
Cached Medicine News:Health News:The Pennsylvania Breast Cancer Coalition Hosts Seminar on Free Breast Cancer Treatment Program 2Health News:Photo: Two Men Raising Awareness of HIV/AIDS by Running Minimum of a Marathon a Day from San Francisco to Los Angeles 2Health News:Photo: Two Men Raising Awareness of HIV/AIDS by Running Minimum of a Marathon a Day from San Francisco to Los Angeles 3Health News:Herceptin helps women with multiple chromosomes containing HER2 gene, study finds 2Health News:Premier Children's Charity Sets Fundraising Record With Back-to-Back Events 2Health News:Premier Children's Charity Sets Fundraising Record With Back-to-Back Events 3Health News:Premier Children's Charity Sets Fundraising Record With Back-to-Back Events 4Health News:American Society for Aesthetic Plastic Surgery and American Society of Plastic Surgeons Offer Patient Advisory for those Affected by Fig LipoDissolve Closures 2Health News:American Society for Aesthetic Plastic Surgery and American Society of Plastic Surgeons Offer Patient Advisory for those Affected by Fig LipoDissolve Closures 3Health News:As More Americans Live to 100, Long Term Care Insurance Leader Gives Health Assist 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: